Related Experiment Video
Updated: Aug 14, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
[Fluctuation of C-reactive protein levels in acute coronary syndrome]
Insights
Early atorvastatin use in acute coronary syndrome patients rapidly reduced C-reactive protein levels. This study highlights atorvastatin
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Acute coronary syndrome (ACS) is a critical condition often associated with inflammation.
- C-reactive protein (CRP) is a key inflammatory marker.
- Statins, like atorvastatin, are known for their lipid-lowering and anti-inflammatory effects.
Purpose of the Study:
- To investigate the impact of early atorvastatin administration on plasma C-reactive protein (CRP) levels in ACS patients.
- To determine if atorvastatin influences the inflammatory marker CRP in the acute phase of ACS.
Main Methods:
- A study involving 32 ACS patients (within 3 hours of pain onset).
- Patients were randomized into two groups: one receiving atorvastatin (40 mg/day) and a control group.
- Plasma high-sensitivity C-reactive protein (hs-CRP) levels were measured at baseline, day 7, and day 14.
Main Results:
- CRP levels increased in both groups by day 7.
- In the atorvastatin group, CRP levels decreased by 16.54% by day 14 (p=1.7).
- In the control group, CRP levels increased by 9.12% by day 14 (p<0.0005).
Conclusions:
- Early initiation of atorvastatin in ACS patients is associated with a rapid reduction in CRP levels.
- Atorvastatin demonstrates a significant anti-inflammatory effect in the acute phase of acute coronary syndrome.
Abstract:
The aim of the study was to find out whether early use of atorvastatin in patients with acute coronary syndrome is associated with rapid changes of plasma levels of the marker of inflammation -- C-reactive protein. 32 patients (15 male, 17 female; no more then 3 hours from pain onset, age 61+/-10 years) treated with AHA recommendations, were assigned to the two groups. In the I group (n=17) patients received atorvastatin (liprimar) 40 mg/day, II group (n=15) represented the control group. Plasma level of C-reactive protein (hs-CRP) was assessed by highly sensitive method at baseline, on days 7 and 14. Baseline clinical characteristics and C-reactive protein level were similar in all groups. C-reactive protein level was increased in both groups from the baseline on day 7 (p<0.01). In group I C-reactive protein level was decreased by 16.54% from the baseline on day 14 (from 22.48+/-1.65 to 18.76+/-1.55 mg/l, p=1.7). In II group C-reactive protein level was increased by 9.12% from baseline on day 14 (from 22.79+/-1.67 to 24.87+/-1.24 mg/l, p<0.0005). In patients with acute coronary syndrome early use of atorvastatin was associated with rapid decrease of C-reactive protein level.
Related Concept Videos
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:30Acute Coronary Syndrome I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:26Acute Coronary Syndrome V: Nursing Management